Literature DB >> 8319516

Evidence of ex vivo and in vitro impaired neutrophil oxidative burst and phagocytic capacity in type 1 diabetes mellitus.

W Marhoffer1, M Stein, L Schleinkofer, K Federlin.   

Abstract

In this study neutrophil (PMN) oxidative burst activity was investigated ex vivo and in vitro in comparison to the PMN-phagocytic functions ingestion and bacterial killing in poorly-controlled type 1 diabetic patients. Luminol enhanced chemiluminescence in response to phorbolesters as a measure of oxidative burst was assessed in a parallel detecting microtiterplate luminometer in 40 poorly-controlled type 1 diabetic subjects. PMN ingestion was measured with [3H]thymidine-labelled Staphylococcus aureus in a kinetic radiometric assay. Microbicidal activity was determined by pure plate counting of surviving bacteria (colony forming units, cfu) after defined pmn challenge. PMNs of type 1 diabetic subjects showed a highly significant reduction of peak CL response in response to PMA compared to nondiabetic controls (P < 0.001) and PMN ingestion (51.8 +/- 4.6%) and bacterial killing (28.6 +/- 3.2%) were reduced as well (78.2 +/- 5.2% (IN) and 18.4 +/- 4.1% (BK), P < 0.01, respectively). The in vitro data displayed impaired PMN oxidative burst activity at glucose concentrations > or = 13.8 mmol/l whereas PMN IN and BK were significantly reduced at glucose levels > or = 27.75 mmol/l. In the control group there was a positive correlation of peak CL response and IN as well as BK (P < 0.05); in type 1 diabetic patients this was also true, but did not reach statistical significance. The data obtained in this study clearly demonstrated impaired PMN oxidative burst activity and markedly reduced ingestion and bacterial killing in type 1 diabetic patients ex vivo and in vitro.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8319516     DOI: 10.1016/0168-8227(93)90112-i

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  27 in total

Review 1.  Ethical problems of evaluating a new treatment for melioidosis.

Authors:  Allen C Cheng; Michael Lowe; Dianne P Stephens; Bart J Currie
Journal:  BMJ       Date:  2003-11-29

2.  Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection.

Authors:  Larry M. Baddour
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

3.  Abdominal pain from a thoracic epidural abscess.

Authors:  Erle Chuen-Hian Lim; Raymond C S Seet
Journal:  J Gen Intern Med       Date:  2006-02       Impact factor: 5.128

Review 4.  Impaired wound healing: facts and hypotheses for multi-professional considerations in predictive, preventive and personalised medicine.

Authors:  Eden Avishai; Kristina Yeghiazaryan; Olga Golubnitschaja
Journal:  EPMA J       Date:  2017-03-03       Impact factor: 6.543

Review 5.  Diabetes and immunity to tuberculosis.

Authors:  Nuria Martinez; Hardy Kornfeld
Journal:  Eur J Immunol       Date:  2014-02-16       Impact factor: 5.532

Review 6.  Melioidosis: epidemiology, pathophysiology, and management.

Authors:  Allen C Cheng; Bart J Currie
Journal:  Clin Microbiol Rev       Date:  2005-04       Impact factor: 26.132

7.  Randomized prospective controlled trial of recombinant granulocyte colony-stimulating factor as adjunctive therapy for limb-threatening diabetic foot infection.

Authors:  F de Lalla; G Pellizzer; M Strazzabosco; Z Martini; G Du Jardin; L Lora; P Fabris; P Benedetti; G Erle
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  Acute gonococcal arthritis: an unusual host and pathogen combination.

Authors:  D A Lewis; L M Pollock; J Randell; P Wilson; P G Kopelman
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

Review 9.  Inflammation and neuropeptides: the connection in diabetic wound healing.

Authors:  Leena Pradhan; Christoph Nabzdyk; Nicholas D Andersen; Frank W LoGerfo; Aristidis Veves
Journal:  Expert Rev Mol Med       Date:  2009-01-13       Impact factor: 5.600

10.  Beta-hydroxybutyrate abrogates formation of bovine neutrophil extracellular traps and bactericidal activity against mammary pathogenic Escherichia coli.

Authors:  Navit Grinberg; Sharon Elazar; Ilan Rosenshine; Nahum Y Shpigel
Journal:  Infect Immun       Date:  2008-04-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.